The pathophysiology of asthma involves an intricate network of good target for asthma therapy. Using systemic administra- This study sought to examine further the role of Gal-3 and reversible airflow limitation. This disease develops with in an in vivo model. We used Brown-Norway rats, a wellepisodes of wheezing, coughing, shortness of breath, and characterized model with several inflammatory and immunoairway hyperresponsiveness to nonspecific stimuli. Eosinologic features resembling those of asthma, that is, airway philic inflammation is characterized by eosinophil accumulaeosinophilic inflammation, development of airway hypertion in the airways, caused by a release of interleukin (IL)-5 reactivity, elevated IgE serum levels, and expression of Th2 by Th2 lymphocytes and other cells (1, 2). This IL is the cytokines (14). main growth, differentiation, and survival factor for eosinoOur results demonstrate that intratracheal instillation of phils and, indeed, is essential for initiation of allergenplasmid-Gal-3 (pGal-3) in sensitized and antigen-challenged induced eosinophilic airway inflammation (3, 4). rats by inhalation leads to an improvement, not only regardThe severity of asthma is linked to the degree of airway ing the cellular inflammatory infiltrate, but also in pulmonary eosinophilia (5). In humans, eosinophils may contribute to function. There is normalization in both eosinophil and T cell the pathogenesis of asthma by releasing a number of inflamnumbers and a strong inhibition of IL-5 mRNA in the lungs matory mediators and toxic products, including oxygen and of treated rats. These results suggest a novel therapeutic nitrogen radicals (6) and cationic proteins, which can severely approach for asthma treatment. damage the airway epithelium and increase airway reactivity.
and airway hyperresponsiveness may be prevented (7, 8) . ognition site. Gal-3 is expressed in a variety of tissues and cell nary function. We found that instillation of galectin-3 gene in these types (9) . This protein is localized mainly in the cytoplasm, rats led to normalization of the eosinophil and T cell count in bronalthough significant amounts can also be detected in the choalveolar lavage fluid and that there was a strong concomitant nucleus, on the cell surface, and in the extracellular environinhibition of IL-5 mRNA in the lungs. As a consequence, galectinment (10). Gal-3 has been implicated in different processes, This study sought to examine further the role of Gal-3 and reversible airflow limitation. This disease develops with in an in vivo model. We used Brown-Norway rats, a wellepisodes of wheezing, coughing, shortness of breath, and characterized model with several inflammatory and immunoairway hyperresponsiveness to nonspecific stimuli. Eosinologic features resembling those of asthma, that is, airway philic inflammation is characterized by eosinophil accumulaeosinophilic inflammation, development of airway hypertion in the airways, caused by a release of interleukin (IL)-5 reactivity, elevated IgE serum levels, and expression of Th2 by Th2 lymphocytes and other cells (1, 2) . This IL is the cytokines (14). main growth, differentiation, and survival factor for eosinoOur results demonstrate that intratracheal instillation of phils and, indeed, is essential for initiation of allergenplasmid-Gal-3 (pGal-3) in sensitized and antigen-challenged induced eosinophilic airway inflammation (3, 4) . rats by inhalation leads to an improvement, not only regardThe severity of asthma is linked to the degree of airway ing the cellular inflammatory infiltrate, but also in pulmonary eosinophilia (5) . In humans, eosinophils may contribute to function. There is normalization in both eosinophil and T cell the pathogenesis of asthma by releasing a number of inflamnumbers and a strong inhibition of IL-5 mRNA in the lungs matory mediators and toxic products, including oxygen and of treated rats. These results suggest a novel therapeutic nitrogen radicals (6) and cationic proteins, which can severely approach for asthma treatment. damage the airway epithelium and increase airway reactivity.
The role of IL-5 in this disease would seem to make it a METHODS Plasmid DNA Preparation
Ten micrograms of total lung Gal-3 gene (a plasmid gift from Dr. F.-T. Liu, La Jolla Institute for protein from different groups of Allergy and Immunology, San Diego, CA) was cloned into an eukaryotreated rats were analyzed by sotic expression vector pEGFP plasmid (Clontech, Palo Alto, CA). Empty dium dodecyl sulfate-polyacrylpEGFP plasmid and pEGFP-antisense Gal-3 were used as controls. pDNA was purified using the Wizard DNA purification system (Proamide gel electrophoresis, folmega, Madison, WI) and stored at Ϫ20ЊC in pyrogen-free saline.
lowed by Western blot stained with anti-Gal-3 monoclonal an- (10) . Polymerase chain reaction (PCR) to Gal-3 was (OA) represents lysates from performed on 5-10 l of DNA product in a volume of 50 l. The primers were designed in accordance with a published sequence (16).
Gal-3 Expression in Lung by Immunoblotting and Polymerase
OVA. Lane 4 (pC) represents lysates from pEGFP, and Lanes 5
Bronchoalveolar Lavage, Cell Analysis, and RNA Preparation and 6 (pGal-3) represent lysates from pEGFP-Gal-3. (B ) Gal-3 amplification by PCR in the same samples. Groups are identical as in A. Lane 7 Cells obtained by bronchoalveolar lavage (BAL; 5 ml of saline for three washes) were counted and used for RNA extraction and for cytometric (Cϩ) represents a positive control plasmid with Gal-3. ␤-Actin was used analysis. Briefly, 1 ϫ 10 6 cells/ml were incubated for 30 minutes with as normalized control. a saturating concentration of fluorescein isothiocyanate-labeled antirat CD3 (G4.18), anti-rat granulocytes (HIS48), or anti-rat CD49d (integrin ␣4␤1) to detect T cells, granulocytes, and eosinophils, respectively. The monoclonal antibodies were purchased from PharMingen anti-Gal-3 monoclonal antibody. In Figure 1A , Gal-3 was (San Diego, CA) and were analyzed using a flow cytometer (Epics strongly detected in the lung of rats, which received pGal-3 XLMCL; Coulter, Hialeah, FL).
(Lanes 5 and 6). The other groups, which had not received Total RNA was isolated from BAL cells and lungs by an RNeasy plasmid with Gal-3 (SS, OA, pC), presented a minimal constitukit (Qiagen, Chatsworth, CA) and were treated with Dnase I (Promega). RNA was measured by spectrophotometry, and 0.5-1 g was tive expression of Gal-3. Recombinant Gal-3 was used as a posiused for the first-strand cDNA synthesis with avian myeloblastosis virus tive control (Lane 1). Lane 2 (SS) corresponded to lung lysates (AMV) reverse transcriptase (Promega).
from SS group, Lane 3 (OA) to lysates from OVA group, and Lane 4 (pC) to lysates from pEGFP group.
Real-Time Quantitative PCR to IL-5
These data were confirmed by PCR, and similar results were Primers were designed from a published sequence, and amplified prodobtained. Figure 1B demonstrates that the Gal-3 signal is easily uct was 298 bp (17). We used LightCycler-FastStart DNA Master SYBR detected in lung lysates from rats treated with pGal-3. In Green I for PCR. Samples were normalized at 0.5 g of RNA free of 
Gal-3.

Determination of Total Serum IgE and Specific Antibodies
Effect of pGal-3 on Quantitative Expression of IL-5 Gene in BAL Cells Total IgE levels were determined as described (18). All reagents were a gift from Professor H. Bazin (University of Louvain, Belgium). Spe- Forced expiration maneuvers were performed by inflating the lung Figure 2 . Quantitation of IL-5 gene to 30 cm H 2 O and rapidly deflating to residual volume with a negative expression in lung from different pressure of Ϫ40 cm H 2 O. Forced vital capacity (FVC) and expiratory flow at 75% of FVC (F75) were derived directly from the expiratory groups of rats (see text). mRNA was flow-volume curves as previously described (15, 19 We set out to study the expression of the encoded protein in
OVAϩpEGFP (SS ϭ hatched bars; OVAϩpEGFP ϭ black bars; OVA ϭ white bars; OVAϩpEGFPϪGal-3 ϭ gray bars).
lung tissue. Immunoblotting of lung lysates was performed using 90.7% reduction vis-à -vis the OVA-treated group. Data shown tized rats had high levels of total and specific serum IgE. As can in Figure 2 are the mean Ϯ SEM of n ϭ 4 rats from each group be seen in Table 1 , there were no detectable changes in IgE from (p Ͻ 0.05).
sensitized rats treated with plasmid with Gal-3 and OVAϩempty plasmid. Data in Table 1 indicate that Gal-3 interferes neither
Administration of pGal-3 Prevents Cellular Infiltration
with total nor with specific IgE synthesis.
of Airways
Determination of specific IgG antibodies against immunizing Cellular airway inflammation is a pivotal event in allergenagents showed that neither the response against OVA nor that induced airway sensitization, and as expected, the downregulation against diphtheria was modified in treated rats. Antibody titers of the IL-5 gene produced changes in the composition of cells were similar across all sensitized groups (data not shown). from the BAL. Figure 3A shows that after sensitization and airway challenge with OVA and instillation with empty plasmid
Pulmonary Function Recovery after Intratracheal Instillation
(OVAϩpEGFP) or antisense plasmid (OVAϩpEGFPϪAS, n ϭ of pGal-3 10), the absolute number of BAL cells registered a significant
We were also interested in ascertaining whether the observed increase compared with nonsensitized (SS) rats (35.24 Ϯ 9 ϫ improvement in eosinophilic and T cell inflammation reflected 10 6 and 47.66 Ϯ 19 ϫ 10 6 cells versus 6.7 Ϯ 0.9 ϫ 10 6 cells, n ϭ a recovery of lung function. Figure 4 shows the pulmonary pres-8). In contrast, in the OVAϩpEGFPϪGal-3-treated group (n ϭ sure in all four groups of OVA-sensitized rats. Pulmonary pres-17), we observed a significant decrease in the total BAL cell sure was quantified in terms of the percentage change compared number (15.57 Ϯ 7 ϫ 10 6 cells) as against the OVA group with the SS group (n ϭ 8), considered as 100%. A significant (40.40 Ϯ 20 ϫ 10 6 cells, n ϭ 15, p Ͻ 0.001). The percentage of different cell populations in BAL was also increase in pulmonary pressure was found in the OVA (n ϭ examined. The main cell populations found in OVA-sensitized 10), OVAϩpEGFPϪAS (n ϭ 10), and OVAϩpEGFP (n ϭ 10) rats were T cells and eosinophils, although some neutrophils groups, namely, 147.83 Ϯ 7.58%, 134.30 Ϯ 7%, and 150.4 Ϯ (1-13%) were observed in BAL from all groups. Treatment with 8.2%, respectively. In contrast, the pulmonary pressure of the pGal-3 (OVAϩpEGFPϩGal-3) altered the cell profile of OVAOVAϩpEGFPϪGal-3 group (n ϭ 17) decreased toward control sensitized rats, resulting in a significant reduction in eosinophils level (118.18 Ϯ 6.31%), thus proving significantly different from (69.6% decrease) and T cells (62.4% decrease) in BAL fluid the OVA group (p Ͻ 0.005). (p Ͻ 0.005; Figure 3B ). No differences were found in total cell In Figure 5 , FVC and expiratory flow after F75 are expressed number and cell populations when OVAϩempty plasmid (OVAϩ as the percentage of decline with respect to the SS group. FVC pEGFP) and OVA antisense Gal-3 (OVAϩpEGFPϪAS) were and F75 were significantly decreased in both the OVA, OVAϩ compared. These results indicate that administration of pEGFPpEGFPϪAS, and OVAϩpEGFP groups vis-à -vis the SS group. Gal-3 in lung modulates allergen-induced BAL eosinophilia and In contrast, rats receiving Gal-3 partially returned to control T cell accumulation. values, with both F75 and FVC being significantly different from
Levels of Total Serum IgE and Specific Antibodies
that of the OVA group (p Ͻ 0.005). We wished to ascertain whether treatment with plasmid-encoding Gal-3 might alter total and specific IgE levels. OVA-sensi- 
pEGFPϪGal-3 ϭ gray bars).
DNA uptake, and genes express a biologically active protein in (35, 36) . Furthermore, IL-5 enAirway inflammation in asthma is a complex phenomenon that hances eosinophil adhesion to bronchial epithelial cell (37) . It is predominantly driven by Th2-type cells. An understanding of is therefore not surprising that by decreasing IL-5 we decreased the molecular mechanisms regulating Th2 cytokine production T cells and eosinophils in the airways. in vivo is a key factor for development of novel therapies (20, 21).
The effect observed when using plasmid with Gal-3 gene The data presented here show that intratracheal deposition is not due to nonspecific effects from naked plasmid, such as of a vector with the gene that codifies for Gal-3 in Brown-Norway immunostimulatory DNA sequences, as antisense Gal-3 failed rats causes a blunting of some Th2 effects locally in the lung to produce any therapeutic effect. (eosinophil influx and functional pulmonary parameters). Thus, Recent studies describe a diversification in the relationship Gal-3 plays an important role in the downregulation of IL-5 between eosinophils, airway hyperresponsiveness, and T cells. gene expression and the ensuing amount of eosinophils and T This is dependent on several factors, for example, the animal cells in BAL. As a consequence, there is an improvement in model versus humans, and within the animal model itself, the both the eosinophilic inflammation and functional respiratory specific strain and manner of immunization (38-41). All of these parameters.
parameters must be taken in account when it comes to validating Gal-3 belongs to a family of soluble proteins with affinity for any given therapy, thereby rendering comparison between differ-␤-galactose-containing oligosacharides. In a previous study, we ent strategies difficult. With respect to the results obtained with demonstrated that Gal-3 downregulates IL-5 gene expression in anti-IL-5 antibodies, it is important to point out that our model different cell types, using CD32 (Fc␥RII) as receptor (10, 13) .
showed a decrease in both eosinophils and CD3ϩ T cells. This In addition, it probably works through inhibition of GATA-3, may explain why our rats underwent a significant recovery of the main nuclear factor implicated in IL-5 gene regulation (22). pulmonary function in both expiratory flows and pulmonary Other authors have suggested a role for Gal-3 as a negative pressures, not detected by anti-IL-5 humanized antibodies (32) . growth regulator (23) and as an inhibitor of the transcription Recently, targeted disruption of the Gal-3 gene has been of the granulocyte macrophage-colony-stimulating factor-driven described as resulting in attenuated peritoneal inflammatory reresponsive genes in rat mononuclear bone marrow cells, with an sponses in thioglycolate-treated mice, caused mainly by lower ability to suppress bone marrow cell proliferation in vivo (24) . numbers of macrophages. Furthermore, there were consistently IL-5 is one of the main regulatory cytokines that modulates more eosinophils in Gal-3 Ϫ/Ϫ mice (42) . According to our results, eosinophils, the major inflammatory effector cells in allergic there is an inverse correlation between absence of Gal-3 and disorders (25, 26). Thus, IL-5 promotes eosinophil differentiaincreased numbers of eosinophils. Total serum IgE level was tion, CD34ϩ eosinophil progenitor mobilization from bone marnot altered with pGal-3 treatment, in line with our previous data row cells, and eosinophil CCR3 expression in asthma; increases in which Gal-3 was shown to have no detectable effect on the recruitment of eosinophils from circulation; prolongs survival of IL-4 gene (13). Thus, other authors have demonstrated that eosinophils; and primes eosinophils for degranulation and rewhereas anti-IL-5 does prevent airway inflammation, anti-IgE lease of toxic metabolites (27) (28) (29) (30) . These effects make IL-5 an does not (8) . Other alternatives tested recently include the use excellent target for treatment of airway eosinophilic inflammaof an IL-5 antisense oligonucleotide in mouse models of asthma, tion (31) .
with inhibition of antigen-induced eosinophilia and late-phase As mentioned earlier, our previous studies in vitro indicated airway hyperresponsiveness being reported (22). Recently, inhithat Gal-3 induces downregulation of IL-5 gene in several cell bition of antigen-induced eosinophilia and airway hyperrespontypes (10, 13) . For this reason, we used Gal-3 in the treatment siveness has been reported, using antisense oligonucleotides diof antigen-specific airway inflammation in a rat model. Gene rected against the common ␤ chain of IL-3, IL-5, granulocyte therapy may have some advantages over conventional pharmamacrophage-colony-stimulating factor receptors in a rat model cologic treatment. First, it allows overexpression of Gal-3 in the of allergic asthma (43) . target area intracellularly, its natural location; second, one is not Whereas treatment with Gal-3-inhibiting IL-5 expression delimited by the amount of material. Finally, unlike other anti-IL-5 creased eosinophil airway accumulation and prevented developtherapies, one avoids parenteral administration (32) . Because ment of specific airway hyperresponsiveness, there was no interthe effect of Gal-3 is highly IL-5 selective, there are no collateral ference with secretion of other cytokines, because IL-4, IL-2, effects on other ILs. Hence, no other alterations to the immune and ␥-interferon production in BAL were not modified with response were to be expected in the treated animals. Direct gene Gal-3 treatment (measured by PCR, data not shown). B cell immunoglobulin production was not altered because specific IgG transfer was used because it has been shown to result in rapid Aceituno E, Takai T, Verbeek S, Palomino P, et al. Interaction between and IgE and total IgE serum levels were similar for all sensitized galectin-3 and Fc␥RII induces down-regulation of IL-5 gene: implicarats (whether or not treated with Gal-3). 
